

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for May 2023

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Abiraterone	Zytiga	ABIRATERONE ACETATE _E	500 mg	tablet	02529629
Dr. Reddy's Laboratories Canada Inc.	Reddy-Abiraterone	Zytiga	ABIRATERONE ACETATE	500 mg	tablet	02533251
Jamp Pharma Corporation	Gabapentin	Neurontin	GABAPENTIN	600 mg	tablet	02432072
Jamp Pharma Corporation	Gabapentin	Neurontin	GABAPENTIN	800 mg	tablet	02432080